Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report-PR Newswire APAC
- Written by PR Newswire Asia - Daily Bulletin Au RSS
Highlights:
- FDA provides guidance for ATH434 development pathway
- Company compliant with minimum NASDAQ price
- End of period cash balance of $9.2M bolstered by $1.5M following issue of shares on 2 July
MELBOURNE, Australia and SAN FRANCISCO, July 31, 2020 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the...
Read more: Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report-PR Newswire APAC